IL1B and rheumatoid arthritis: In this study, standard-specific visible and biochemical RA markers were taken into consideration for monitoring inflammation and disease progression, and were used for the assessment of treatment efficacy, including paw and knee swelling, locomotion behavior, limb redness and body weight loss, levels of the serum cytokines TNF-α, IL-6, and IL-1β, acute phase protein (CRP) and rheumatoid factor (RF) induction levels, and joint histopathology.